Showing results (21-30 of 40) with videos related to
Sort By:
Pageof 4
Journal of Medicinal Chemistry|January 6, 2006
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar leadIon Niculescu-Duvaz, Esteban Roman, Steven R Whittaker, et al.Journal of Medicinal Chemistry|May 14, 2008
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffoldIon Niculescu-Duvaz, Esteban Roman, Steven R Whittaker, et al.Bioorganic & Medicinal Chemistry|February 5, 2013
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituentsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.Oncogene|June 23, 2004
B-RAF is a therapeutic target in melanomaMaria Karasarides, Antonio Chiloeches, Robert Hayward, et al.Cell|February 10, 2010
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFSonja J Heidorn, Carla Milagre, Steven Whittaker, et al.Pigment Cell & Melanoma Research|December 17, 2009
Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethalityNathalie Dhomen, Silvy Da Rocha Dias, Robert Hayward, et al.Cancer Research|September 3, 2010
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAFSteven Whittaker, Delphine Ménard, Ruth Kirk, et al.Cell|March 24, 2004
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAFPaul T C Wan, Mathew J Garnett, S Mark Roe, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrugAstrid Mayer, Roslyn J Francis, Surinder K Sharma, et al.Molecular Cancer Therapeutics|October 22, 2015
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell CarcinomaVictoria L Bridgeman, Elaine Wan, Shane Foo, et al.Pageof 4